AstraZeneca to Buy Icosavax for Up to 1.1 Bln -- Update

ICVXDelisted Stock  USD 9.02  0.12  1.31%   
Slightly above 62% of Icosavax's investor base is looking to short. The analysis of current outlook of investing in Icosavax suggests that many traders are alarmed regarding Icosavax's prospects. Icosavax's investing sentiment can be driven by a variety of factors including economic data, Icosavax's earnings reports, geopolitical events, and overall market trends.
  
By Ian Walker AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to 1.1 billion in a deal that expands its...

Read at marketwatch.com
marketwatch News
  

Icosavax Fundamental Analysis

We analyze Icosavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icosavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icosavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Icosavax is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Icosavax Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icosavax stock to make a market-neutral strategy. Peer analysis of Icosavax could also be used in its relative valuation, which is a method of valuing Icosavax by comparing valuation metrics with similar companies.

Peers

Icosavax Related Equities

XFORX4 Pharmaceuticals   11.43   
0%
100.0%
ELDNEledon Pharmaceuticals   9.39   
0%
82.0%
IMMXImmix Biopharma   7.11   
0%
62.0%
HEPAHepion Pharmaceuticals   4.69   
0%
41.0%
PDSBPDS Biotechnology   1.86   
0%
16.0%
HOOKHookipa Pharma   1.61   
0%
14.0%
DAWNDay One   1.53   
0%
13.0%
MREOMereo BioPharma   1.40   
0%
12.0%
ABOSAcumen Pharmaceuticals   0.44   
0%
3.0%
INZYInozyme Pharma   0.37   
3.0%
0%
TERNTerns Pharmaceuticals   1.58   
13.0%
0%
AMLXAmylyx Pharmaceuticals   3.48   
30.0%
0%
CNSPCns Pharmaceuticals   8.33   
72.0%
0%
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Icosavax Stock

If you are still planning to invest in Icosavax check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Icosavax's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets